Shift versus no-shift in local regularizations of Chern-Simons theory

We consider a family of local BRS-invariant higher covariant derivative regularizations of $SU(N)$ Chern-Simons theory that do not shift the value of the Chern-Simons parameter $k$ to k+\,{\rm sign}(k)\,\cv at one loop.Comment: phyzzx, 6 pages, FTUAM 94/8, NIKHEF-H 94/14 and UPRF 93/39

Supersymmetric Yang-Mills-Chern-Simons theory

We prove that three-dimensional N=1 supersymmetric Yang-Mills-Chern-Simons theory is finite to all loops. This leaves open the possibility that different regularization methods give different finite effective actions. We show that for this model dimensional regularization and regularization by dimensional reduction yield the same effective action.Comment: 6 pages, 1 figure, latex, espcrc2. Contribution to the Proceedings of the 30th Ahrenshoop Symposium on the Theory of Elementary Particles, edited by D. Lust, H.-J. Otto and G. Weigt, to appear in Nuclear Physics B, Proceedings Supplemen

The universality of the shift of the Chern-Simons parameter for a general class of BRS invariant regularizations

We consider a biparametric family of BRS invariant regularization methods of SU(N) Chern-Simons theory (the parameters defining the family taking arbitrary values in \RR^2) and show that the shift $k\to k + sign(k) N$ of the Chern-Simons parameter $k$ occurs for arbitrary values of the family defining parameters. This supports irrefutably the conjecture that the shift of $k$ is universal for BRS invariant regulators.Comment: phyzzx, 7 pages (no figures

The Role of Ivabradine in the Management of Angina Pectoris

Stable angina pectoris affects 2–4 % of the population in Western countries and entails an annual risk of death and nonfatal myocardial infarction of 1–2 % and 3 %, respectively. Heart rate (HR) is linearly related to myocardial oxygen consumption and coronary blood flow, both at rest and during stress. HR reduction is a key target for the prevention of ischemia/angina and is an important mechanism of action of drugs which are recommended as first line therapy for the treatment of angina in clinical guidelines. However, many patients are often unable to tolerate the doses of beta blocker or non-dihydropyridine calcium antagonists required to achieve the desired symptom control. The selective pacemaker current inhibitor ivabradine was developed as a drug for the management of patients with angina pectoris, through its ability to reduce HR specifically. The available data suggest that ivabradine is a well-tolerated and effective anti-anginal agent and it is recommended as a second-line agent for relief of angina in guidelines. However, recent clinical trials of ivabradine have failed to show prognostic benefit and have raised potential concerns about safety. This article will review the available evidence base for the current role of ivabradine in the management of patients with symptomatic angina pectoris in the context of stable coronary artery disease

Two-Loop Finiteness of Chern-Simons Field Theory in Background Field Method

We perform two-loop calculation of Chern-Simons in background field method using the hybrid regularization of higher-covariant derivative and dimensional regularization. It is explicitly shown that Chern-Simons field theory is finite at the two-loop level. This finiteness plays an important role in the relation of Chern-Simons theory with two-dimensional conformal field theory and the description of link invariant.Comment: RevTex, 13 pages. The proof of the existence of the large topological mass limit has been proved. Some typewritten mistakes have been correcte